The read at a glance
Computed from the FY2025 annual filing. Full history and the components behind each score are in the app.
- Distress risk · Altman Z-Score 6.56 — safe zoneOK
- Earnings-manipulation signal · Beneish M -1.24 — flag raised, worth a closer lookWatch
- Earnings quality 59/100 — worth a closer lookWatch
Where the revenue comes from
Fiscal 2025, as HUTCHMED (China) Ltd reports it. History and quarterly detail are in the app.
- Oncology Or Immunology$285.5M
- Other Ventures$263.0M
Latest filings
- 6-K · Company announcement (foreign filer)2026-09-03
- 6-K · Company announcement (foreign filer)2026-08-31
- 6-K · Company announcement (foreign filer)2026-08-28
- 6-K · Company announcement (foreign filer)2026-08-18
- 6-K · Company announcement (foreign filer)2026-08-17
In the full recordFree for 14 days
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about HUTCHMED (China) Ltd, every answer cited to the official filings🔒
- The Intelligence Brief — added when HUTCHMED (China) Ltd's brief passes our SEC-figure check🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.